Moderna's Q2 Revenue and Net Loss Overview

Moderna Inc. announced a significant 41% decrease in its second-quarter revenue for fiscal 2025, totaling $142 million. Despite this downturn, the figures surpassed market expectations, showcasing resilience in a challenging economic landscape.

Financial Performance and Market Reaction

The biotechnology behemoth reported a net loss of $825 million, an improvement from the $1.3 billion loss recorded in the same quarter of the previous year. The diluted loss per share also saw a positive shift, decreasing to $2.13 from $3.33.

Leadership's Strategic Adjustments

CEO Stephane Bancel highlighted adjustments to the 2025 financial framework, including a $300 million reduction in the expected revenue range's upper limit due to shipment timing. Additionally, Moderna aims to cut annual operating expenses by approximately $400 million, reflecting a commitment to financial discipline.

Market Impact: Moderna's shares experienced a 5.55% decline in premarket trading, settling at $27.92 per share.